IMP321: Ph I TACTI-mel ongoing

A DSMB recommended continuation of the open-label, Australian Phase I TACTI-mel trial of subcutaneous IMP321 every 2 weeks plus Keytruda pembrolizumab after 1 mg IMP321 showed no safety concerns. The ...